Array

Visual Financials
Company Name: Array BioPharma Inc
Ticker Symbol: ARRY
CIK Number: 0001100412
WWW Address: http://www.arraybiopharma.com
CEO: Ron Squarer
No. of Employees: 198
Common Issue Type: CS
Business Description:Array BioPharma, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

 
Industry Information: DRUGS - Biotechnology [more like this]
 Price  Day Change  Bid  Ask  Open  High  Low  Volume 
 3.65 Unchanged 0.0 3.6 3.73  3.74 3.63 -
 Market Cap (mil) Shares Outstanding (mil) Beta EPS DPS P/E Yield 52-Wks-Range
 529.3 145.0 0.00 -0.65 0.00 0.0 0.0 5.57 - 2.39
KEY FIGURES (Latest Twelve Months - LTM)
Yesterday's Close3.65$
PE Ratio - LTM0.0
Market Capitalisation529.3mil
Latest Shares Outstanding145.0mil
Earnings pS (EPS)-0.65$
Dividend pS (DPS)0.00¢
Dividend Yield0.0%
Dividend Payout Ratio%
Revenue per Employee778,977$
Effective Tax Rate0.0%
Float107.9mil
Float as % of Shares Outstanding0.7%
Foreign Sales115mil
Domestic Sales22mil
Selling, General & Adm/tive (SG&A) as % of Revenue0.30%
Research & Devlopment (R&D) as % of Revenue1.20%
Gross Profit Margin83.2%
EBITDA Margin-58.3%
Pre-Tax Profit Margin-67.3%
Assets Turnover75.1%
Return on Assets (ROA)-50.6%
Return on Equity (ROE)-3933.1%
Return on Capital Invested (ROCI)-72.9%
Current Ratio3.0
Leverage Ratio (Assets/Equity)
Interest Cover-7.5
Total Debt/Equity (Gearing Ratio)
LT Debt/Total Capital0.0%
Working Capital pS0.71$
Cash pS0.00$
Book-Value pS-0.26$
Tangible Book-Value pS-0.26$
Cash Flow pS-0.49$
Free Cash Flow pS-0.51$
KEY FIGURES (LTM): Price info
Price/Book Ratio-13.95
Price/Tangible Book Ratio0.00
Price/Cash Flow-7.4
Price/Free Cash Flow-7.1
P/E as % of Industry Group0.0%
P/E as % of Sector Segment0.0%
 
Balance Sheet (at a glance) in Millions
DIVIDEND INFO
Type of Payment-
Dividend Rate0.00
Current Dividend Yield0.0
5-Y Average Dividend Yield0.0
Payout Ratio0.0
5-Y Average Payout Ratio0.0
Share price performance previous 3 years

Share price performance intraday

 
PRICE/VOLUMEHighLowClose% Price Chg% Price Chg vs. Mkt.Avg. Daily VolTotal Vol
1 Week---6.252,202,70310,749,285
4 Weeks3.773.183.2513.5142,164,20643,284,121
13 Weeks4.653.103.457.011,827,959116,989,376
26 Weeks4.652.602.8429.9241,798,949228,466,535
52 Weeks5.572.394.94-25.2-372,038,867515,833,469
YTD4.652.39--9.6-171,895,082348,695,244
Moving Average5-Days10-Days10-Weeks30-Weeks200-DaysBeta (60-Mnth)Beta (36-Mnth)
3.653.583.643.343.370.000.00
 
GROWTH RATES5-Year
Growh
R² of 5-Year Growth3-Year
Growth
Revenue0.140.70.26
Income0.0
Dividend0.0
Capital SpendingNA
R&D-8.13NA-9.51
Normalized Inc.0.00NA0.00
 
CHANGESYTD vs.
Last YTD
Curr Qtr vs.
Qtr 1-Yr ago
Annual vs.
Last Annual
Revenue %-31.5-47.918.4
Earnings %0.00.00.0
EPS %0.00.00.0
EPS $-0.18-0.080.69
 
SOLVENCY RATIOS
SHORT-TERM SOLVENCY RATIOS (LIQUIDITY)
Net Working Capital Ratio60.90
Current Ratio3.0
Quick Ratio (Acid Test)2.8
Liquidity Ratio (Cash)3.18
Receivables Turnover6.0
Average Collection Period60
Working Capital/Equity0.0
Working Capital pS0.71
Cash-Flow pS-0.49
Free Cash-Flow pS-0.51
FINANCIAL STRUCTURE RATIOS
Altman's Z-Score Ratio0.70
Financial Leverage Ratio (Assets/Equity)0.0
Debt Ratio67.3
Total Debt/Equity (Gearing Ratio)0.00
LT Debt/Equity0.00
LT Debt/Capital Invested203.9
LT Debt/Total Liabilities100.0
Interest Cover-7.5
Interest/Capital Invested9.34
 
VALUATION RATIOS
MULTIPLES
PQ Ratio0.00
Tobin's Q Ratio3.13
Current P/E Ratio - LTM0.00
Enterprise Value (EV)/EBITDA-7.08
Enterprise Value (EV)/Free Cash Flow-6.84
Dividend Yield0.0
Price/Tangible Book Ratio - LTM0.00
Price/Book Ratio - LTM-13.95
Price/Cash Flow Ratio-7.4
Price/Free Cash Flow Ratio - LTM-7.1
Price/Sales Ratio0.00
P/E Ratio (1 month ago) - LTM0.0
P/E Ratio (26 weeks ago) - LTM0.0
P/E Ratio (52 weeks ago) - LTM0.0
5-Y High P/E Ratio-13.2
5-Y Low P/E Ratio-2.4
5-Y Average P/E Ratio0.0
Current P/E Ratio as % of 5-Y Average P/E
P/E as % of Industry Group0.0
P/E as % of Sector Segment0.0
Current 12 Month Normalized P/E Ratio - LTM0.0
PER SHARE FIGURES
LT Debt pS0.91
Current Liabilities pS0.42
Tangible Book Value pS - LTM-0.26
Book Value pS - LTM-0.26
Capital Invested pS0.52
Cash pS - LTM0.00
Cash Flow pS - LTM-0.49
Free Cash Flow pS - LTM-0.51
Earnings pS (EPS)-0.65
 
OPERATING RATIOS
PROFITABILITY RATIOS
Free Cash Flow Margin-53.13
Free Cash Flow Margin 5YEAR AVG-83.05
Net Profit Margin-0.7
Net Profit Margin - 5YEAR AVRG.-0.7
Equity Productivity-3.63
Return on Equity (ROE)-39.3
Return on Equity (ROE) - 5YEAR AVRG.
Capital Invested Productivity1.82
Return on Capital Invested (ROCI)0.0
Return on Capital Invested (ROCI) - 5YEAR AVRG.
Assets Productivity0.80
Return on Assets (ROA)-0.5
Return on Assets (ROA) - 5YEAR AVRG.-0.4
Gross Profit Margin83.2
Gross Profit Margin - 5YEAR AVRG.0.4
EBITDA Margin - LTM-58.3
EBIT Margin - LTM-59.4
Pre-Tax Profit Margin-0.7
Pre-Tax Profit Margin - 5YEAR AVRG.-0.7
Effective Tax Rate0.0
Effective Tax Rate - 5YEAR AVRG.0.0
EFFICIENCY RATIOS
Cash Conversion Cycle651,028
Revenue per Employee778,977
Net Income per Employee
Average Collection Period651,028
Receivables Turnover6.0
Day's Inventory Turnover Ratio
Inventory Turnover0.0
Inventory/Sales0.0
Accounts Payble/Sales7.36
Assets/Revenue1.25
Net Working Capital Turnover1.34
Fixed Assets Turnover10.14
Total Assets Turnover0.8
Revenue per $ Cash2.44
Revenue per $ Plant20.64
Revenue per $ Common Equity0.00
Revenue per $ Capital Invested1.82
Selling, General & Adm/tive (SG&A) as % of Revenue26.3
SG&A Expense as % of Revenue - 5YEAR AVRG.1.0
Research & Devlopment (R&D) as % of Revenue116.5
R&D Expense as % of Revenue - 5YEAR AVRG.116.5

  
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20160926 08:47:03